Pages that link to "Q28239591"
Jump to navigation
Jump to search
The following pages link to Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis (Q28239591):
Displaying 50 items.
- Atypical haemolytic uraemic syndrome with underlying glomerulopathies. A case series and a review of the literature (Q26864297) (← links)
- Hemolytic uremic syndrome: toxins, vessels, and inflammation (Q28083347) (← links)
- Complement System Part II: Role in Immunity (Q28263460) (← links)
- Haemolytic uraemic syndrome (Q30244707) (← links)
- Immunoadsorption for haemolytic uraemic syndrome (Q33397002) (← links)
- Microparticle generation and leucocyte death in Shiga toxin-mediated HUS. (Q33399130) (← links)
- Shiga toxin-associated hemolytic uremic syndrome: advances in pathogenesis and therapeutics (Q33401572) (← links)
- Shigatoxin-associated hemolytic uremic syndrome: current molecular mechanisms and future therapies (Q33402784) (← links)
- STEC-HUS, atypical HUS and TTP are all diseases of complement activation (Q33403359) (← links)
- Renal and neurological involvement in typical Shiga toxin-associated HUS. (Q33403361) (← links)
- A novel murine infection model for Shiga toxin-producing Escherichia coli (Q33403695) (← links)
- Shiga toxins and the pathophysiology of hemolytic uremic syndrome in humans and animals (Q33404640) (← links)
- Comprehensive analysis of glomerular mRNA expression of pro- and antithrombotic genes in atypical haemolytic-uremic syndrome (aHUS). (Q33406356) (← links)
- Shiga toxin 2 reduces complement inhibitor CD59 expression on human renal tubular epithelial and glomerular endothelial cells (Q33407861) (← links)
- Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome (Q33407898) (← links)
- Two patients with history of STEC-HUS, posttransplant recurrence and complement gene mutations (Q33408171) (← links)
- Quiescent complement in nonhuman primates during E coli Shiga toxin-induced hemolytic uremic syndrome and thrombotic microangiopathy. (Q33408183) (← links)
- Current evidence for the role of complement in the pathogenesis of Shiga toxin haemolytic uraemic syndrome (Q33409030) (← links)
- Complement activation associated with ADAMTS13 deficiency in human and murine thrombotic microangiopathy (Q33409285) (← links)
- New insights into Shiga toxin-mediated endothelial dysfunction in hemolytic uremic syndrome (Q33409878) (← links)
- Increased expression of complement regulators CD55 and CD59 on peripheral blood cells in patients with EAHEC O104:H4 infection (Q33410671) (← links)
- Successful treatment of DEAP-HUS with eculizumab (Q33411577) (← links)
- Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab (Q33411810) (← links)
- Shiga toxin promotes podocyte injury in experimental hemolytic uremic syndrome via activation of the alternative pathway of complement (Q33413591) (← links)
- Pathophysiology of atypical hemolytic uremic syndrome. Ten years of progress, from laboratory to patient (Q33413660) (← links)
- Response to Eculizumab in Escherichia coli O157: H7-induced hemolytic uremic syndrome with severe neurological manifestations (Q33415215) (← links)
- Direct acute tubular damage contributes to Shigatoxin-mediated kidney failure (Q33415795) (← links)
- Dynamics of complement activation in aHUS and how to monitor eculizumab therapy (Q33416519) (← links)
- Safe and effective use of eculizumab in the treatment of severe Shiga toxin Escherichia coli-associated hemolytic uremic syndrome (Q33419554) (← links)
- Complement Factor C4d Is a Common Denominator in Thrombotic Microangiopathy (Q33419693) (← links)
- Activation of the alternative pathway of complement during the acute phase of typical haemolytic uraemic syndrome. (Q33420374) (← links)
- The efficacy of recombinant human soluble thrombomodulin for the treatment of shiga toxin-associated hemolytic uremic syndrome model mice (Q33420531) (← links)
- Complement Interactions with Blood Cells, Endothelial Cells and Microvesicles in Thrombotic and Inflammatory Conditions (Q33425421) (← links)
- CFH gene mutation in a case of Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS). (Q33426147) (← links)
- Thrombocytopenia-Associated Multiple Organ Failure and Acute Kidney Injury (Q33426245) (← links)
- Loss of diacylglycerol kinase epsilon in mice causes endothelial distress and impairs glomerular Cox-2 and PGE2 production (Q33430098) (← links)
- Complement and the kidney in the setting of Shiga-toxin hemolytic uremic syndrome, organ transplantation, and C3 glomerulonephritis (Q33432063) (← links)
- Complement in disease: a defence system turning offensive (Q33432423) (← links)
- Human mannose-binding lectin inhibitor prevents Shiga toxin-induced renal injury (Q33433630) (← links)
- Atypical Hemolytic Uremic Syndrome Secondary to Lupus Nephritis, Responsive to Eculizumab (Q33436295) (← links)
- Eculizumab in secondary atypical haemolytic uraemic syndrome (Q33620588) (← links)
- Complement System Part I - Molecular Mechanisms of Activation and Regulation (Q34481071) (← links)
- White matter injury due to experimental chronic cerebral hypoperfusion is associated with C5 deposition (Q35081055) (← links)
- A novel mechanism of bacterial toxin transfer within host blood cell-derived microvesicles (Q35125841) (← links)
- Direct reprogramming of human bone marrow stromal cells into functional renal cells using cell-free extracts (Q35453935) (← links)
- Complement involvement in kidney diseases: From physiopathology to therapeutical targeting (Q35567841) (← links)
- Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome (Q37547496) (← links)
- Novel roles of complement in renal diseases and their therapeutic consequences (Q38101450) (← links)
- The immune system and kidney disease: basic concepts and clinical implications. (Q38137749) (← links)
- The expanding role of therapeutic antibodies (Q38182645) (← links)